• Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications
  • New Bristol facility expands GMP small molecule production capacity and complements recent investments in North America
    • Combined capabilities across Bristol, St. Paul and Minneapolis support customers from discovery through commercial manufacturing